logo

Every week, the Editor-in-Chief selects an Article of the Week from the current issue of BJUI. The abstract is reproduced below and you can click on the button to read the full art[...]
This timely and important article by Bloom et al. [1] highlights findings that warrant special attention in an effort to address and reduce racial disparities in low‐risk prostate [...]
Use of multiparametric magnetic resonance imaging and fusion‐guided biopsies to properly select and follow African‐American men on active surveillance Abstract Objectives To determ[...]
In 2019 is it safe to avoid prostate biopsy in men with Prostate Imaging Reporting and Data System (PI‐RADS) score 1 and 2 lesions reported on their multiparametric MRI (mpMRI)? In[...]
Multiparametric magnetic resonance imaging and follow-up to avoid prostate biopsy in 4259 men Abstract Objective To determine the proportion of men avoiding biopsy because of negat[...]
Every week, the Editor-in-Chief selects an Article of the Week from the current issue of BJUI. The abstract is reproduced below and you can click on the button to read the full art[...]
I would hope the answer to the question posed in the title is a universal ‘yes’; at least that is my experience with this complex and common disease. The concept that in 2019, we h[...]
A recent BJUI article, A four‐group urine risk classifier for predicting outcomes in patients with prostate cancer, by Shea Connell and coworkers from Norfolk and Norwich Universit[...]
The objective of this article is to report outcomes from a multiparametric magnetic resonance imaging‐based active surveillance programme that did not include performing protocol b[...]
This Editorial Comment by Hashim Ahmed discusses re‐thinking active surveillance for the multiparametric magnetic resonance imaging era[...]